Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 31 Jan 2022
CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
31 January 2022 - Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function ...
Posted by Michael Wonder on 31 Jan 2022
MSAC publishes updated agenda for upcoming meeting
28 January 2022 - 11 agenda items for consideration at the 31 March - 1 April 2022 meeting. ...
Posted by Michael Wonder on 31 Jan 2022
Trevena announces submission of new drug application in China for Olinvyk by its partner Jiangsu Nhwa Pharmaceutical
27 January 2022 - Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to intravenous morphine, ...
Posted by Michael Wonder on 31 Jan 2022
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project
28 January 2022 - This article aims at describing the most relevant elements of the drug development process in the paediatric ...
Posted by Michael Wonder on 30 Jan 2022
Building a model of health technology assessment co-operation: lessons learned from EUnetHTA joint action 3
28 January 2022 - The European Network for Health Technology Assessment (EUnetHTA) was established in 2006. During its final project phase ...
Posted by Michael Wonder on 30 Jan 2022
Trade-offs and policy options - using insights from economics to inform public health policy
29 January 2022 - We believe that economics can critically inform public health efforts to address such challenges. ...
Posted by Michael Wonder on 30 Jan 2022
Drug price setting is selfishly shortsighted
28 January 2022 - Prescription drug price-setting proposals keep coming up in Congress with the purported aim of lowering prescription drug ...
Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
Posted by Michael Wonder on 30 Jan 2022
FDA approves Genentech’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
28 January 2022 - Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration and diabetic macular ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 30 Jan 2022
European Commission approves Lorviqua (lorlatinib) as a first-line treatment for ALK positive advanced lung cancer
28 January 2022 - Approval based on results from Phase 3 CROWN trial, showing Lorviqua reduced risk of disease progression ...
Posted by Michael Wonder on 30 Jan 2022
Blueprint Medicines' Ayvakyt (avapritinib) receives positive CHMP opinion for the treatment of adults with advanced systemic mastocytosis
28 January 2022 - Positive opinion based on results from two clinical trials that comprise the largest clinical trial dataset in ...
Posted by Michael Wonder on 30 Jan 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
28 January 2022 - The positive opinion is based on the landmark EMPEROR-Preserved Phase 3 trial, which showed significant outcomes in ...